Abstract：
OBJECTIVE: To derive childhood-onset SLE (cSLE) specific remission definitions for future treat-to-target (T2T) trials, observational studies, and clinical practice.
METHODS: The cSLE International T2T Task Force conducted Delphi surveys exploring paediatric perspectives on adult-onset SLE remission targets. A modified nominal group technique was used to discuss, refine, and agree on the cSLE remission target criteria.
RESULTS: The Task Force proposed two definitions of remission: \'cSLE clinical remission on steroids (cCR)\' and \'cSLE clinical remission off steroids (cCR-0)\'. The common criteria are: (1) Clinical-SLEDAI-2 K = 0; (2) PGA score < 0.5 (0-3 scale); (4) stable antimalarials, immunosuppressive, and biologic therapy (changes due to side-effects, adherence, weight, or when building up to target dose allowed). Criterion (3) in cCR is the prednisolone dose ≤0.1 mg/kg/day (maximum 5 mg/day), whereas in cCR-0 it is zero.
CONCLUSIONS: cSLE definitions of remission have been proposed, maintaining sufficient alignment with the adult-SLE definition to facilitate life-course research.
METHODS: The cSLE International T2T Task Force conducted Delphi surveys exploring paediatric perspectives on adult-onset SLE remission targets. A modified nominal group technique was used to discuss, refine, and agree on the cSLE remission target criteria.
RESULTS: The Task Force proposed two definitions of remission: \'cSLE clinical remission on steroids (cCR)\' and \'cSLE clinical remission off steroids (cCR-0)\'. The common criteria are: (1) Clinical-SLEDAI-2 K = 0; (2) PGA score < 0.5 (0-3 scale); (4) stable antimalarials, immunosuppressive, and biologic therapy (changes due to side-effects, adherence, weight, or when building up to target dose allowed). Criterion (3) in cCR is the prednisolone dose ≤0.1 mg/kg/day (maximum 5 mg/day), whereas in cCR-0 it is zero.
CONCLUSIONS: cSLE definitions of remission have been proposed, maintaining sufficient alignment with the adult-SLE definition to facilitate life-course research.
摘要：
目的：为未来的治疗目标（T2T）试验得出儿童期发病的SLE（cSLE）特定缓解定义，观察性研究，和临床实践。
方法：cSLE国际T2T特别工作组进行了Delphi调查，探讨了成人发病SLE缓解目标的儿科观点。采用改进的名义群技术进行了讨论，精炼,并就cSLE缓解目标标准达成一致。
结果：工作组提出了两种缓解定义：\'类固醇的cSLE临床缓解（cCR）\'和\'类固醇的cSLE临床缓解（cCR-0）\'。常见的标准是：（1）临床SLEDAI-2K=0；（2）PGA评分<0.5（0-3量表）；（4）稳定的抗疟药，免疫抑制,和生物治疗(副作用引起的变化，坚持,体重,或当积累到允许的目标剂量时)。cCR中的标准（3）是泼尼松龙剂量≤0.1mg/kg/天（最大5mg/天），而在cCR-0中它是零。
结论：已经提出了cSLE缓解的定义，与成人SLE定义保持足够的一致性，以促进生命历程研究。
方法：cSLE国际T2T特别工作组进行了Delphi调查，探讨了成人发病SLE缓解目标的儿科观点。采用改进的名义群技术进行了讨论，精炼,并就cSLE缓解目标标准达成一致。
结果：工作组提出了两种缓解定义：\'类固醇的cSLE临床缓解（cCR）\'和\'类固醇的cSLE临床缓解（cCR-0）\'。常见的标准是：（1）临床SLEDAI-2K=0；（2）PGA评分<0.5（0-3量表）；（4）稳定的抗疟药，免疫抑制,和生物治疗(副作用引起的变化，坚持,体重,或当积累到允许的目标剂量时)。cCR中的标准（3）是泼尼松龙剂量≤0.1mg/kg/天（最大5mg/天），而在cCR-0中它是零。
结论：已经提出了cSLE缓解的定义，与成人SLE定义保持足够的一致性，以促进生命历程研究。
